This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Crespo, M. J. Articles by Escobales, N. PubMed PubMed Citation Articles by Crespo, M. J. Articles by Escobales, N. Social Bookmarking                   What's this?

Enalapril and Losartan Are More Effective Than Carvedilol in Preventing Dilated Cardiomyopathy in the Syrian Cardiomyopathic Hamster

^* To whom correspondence should be addressed. E-mail: mcrespo{at}rcm.upr.edu.

	Abstract

To assess the role of the renin–angiotensin (RAS) and adrenergic systems in the development and progression of dilated cardiomyopathy in the Syrian cardiomyopathic hamster (SCH), echocardiographic parameters were evaluated in 6-month-old animals after 5 months of treatment with enalapril (25 mg/kg/day) plus losartan (10 mg/kg/day), or with carvedilol (1 mg/kg/day). Cardiac output indexes (COI) increased by 53% after RAS blockade and by 20% after -blockade in SCH. Moreover, LVEDV and LVESV decreased 30% and 62%, respectively (P < .05) during RAS blockade, whereas ejection fraction (EF) increased by 48%. By contrast, carvedilol reduced LVESV by only 28% (P < .05) and increased EF by only 15% (P < .05). These results suggest that RAS activation plays a critical role in the development of cardiac dysfunction in SCH and that suppression of RAS may be more effective than -blockade in retarding the development of cardiomyopathy in SCH. Owing to timing (pre–heart failure stage) and to the single dose protocol, the implications of this study for human subjects remain to be clarified.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?